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Introduction
============

Cancers of the appendix are very unusual, accounting for only about 0.4% of all gastrointestinal (GI) malignancies \[[@REF1]\]. Furthermore, signet ring cell carcinoma of the appendix (SRCCA) is an exceedingly rare entity. SRCC has been defined by the World Health Organization classification as adenocarcinoma in which the predominant component (more than 50%) is composed of isolated malignant cells containing intracytoplasmic mucin \[[@REF2]\]. Case reports and case series suggest that SRCCA is highly aggressive and has a dismal prognosis \[[@REF3]-[@REF5]\]; however, limited data are available on the discrete characteristics and survival probabilities of this tumor. We aimed to utilize the Surveillance, Epidemiology, and End Results (SEER) database to explore patient and tumor characteristics and to characterize the three- and five-year cancer-specific survival (CSS) probabilities of SRCCA. We also engaged in a review of the current management approaches related to SRCCA. Since SEER is a de-identified, publicly available database, the National Cancer Institute does not mandate institutional review board approval for SEER studies.

Materials and methods
=====================

SRCCA data extracted from the SEER database \[Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2017 Sub (2000-2015)\] were employed to perform this population-based study from January 2000 to December 2015. Primary tumor site was chosen as "Appendix", year of diagnosis selected was "2000 to 2015", and site records of International Classification of Diseases (ICD) codes, third version (ICD-0-3) was used to identify SRCC "8490/3". Tumors that were not microscopically confirmed were excluded. Patients with incomplete survival data or patients with more than one primary tumor were also excluded. No one in our cohort was diagnosed by autopsy and death certificate.

The following primary data were drawn from the database for analysis: year of diagnosis, age at diagnosis, sex, marital status, race, tumor size, tumor grade, the American Joint Committee on Cancer (AJCC) staging system, distant metastasis at the time of diagnosis, surgery of the primary site, cause of death, and survival time. Well-differentiated and moderately-differentiated histologic features were defined as low-grade, while poorly differentiated and undifferentiated histologic types were classified as high-grade. The AJCC Staging Manual third edition was used for tumors diagnosed within the period (2000 through 2004) and the sixth edition was used for tumors diagnosed since 2004. Primary site surgery types were as follows: 1 - no surgery performed (patients who underwent local tumor destruction or excision were included within this category); 2 - partial colectomy (but less than hemicolectomy); 3 - subtotal colectomy; and 4 - total colectomy. No specific code for appendectomy exists in the SEER, but the partial colectomy code reflects and is defined as the performance of an appendectomy.

SEERStat version 8.3.5 was used to search for relevant cases. SPSS Statistics version 23 (IBM, Armonk, NY) and SAS version 9.4 (SAS Institute, Cary, NC) were used for statistical analysis. Descriptive statistics were computed for all variables. Median survival and three- and five-year CSS probabilities for all variables were calculated in months from the time from diagnosis until either death or last known contact. To calculate three- and five-year survival probabilities, survival tables, and Kaplan-Meier curves were utilized. Multivariable Cox regression model was used to calculate the mortality-associated risk factors in those with SRCCA after adjusting for a series of indexes. Deviations between groups were considered statistically significant at a p-value of \<0.05.

Results
=======

We included 527 patients with SRCCA (337 women and 190 men). Table [1](#TAB1){ref-type="table"} illustrates the demographic and tumor-related characteristics of the participants. Women accounted for 63.9% of patients. The mean (SD) age at diagnosis was 56 (12.69) years (range: 27-94 years). Approximately 64% of the included patients were married, and 83.8% were white. Overall, 60% of the tumors were histologically confirmed to be poorly differentiated or undifferentiated tumors of high grade. Tumors invading adjacent organs or those that had grown through the visceral peritoneum accounted for 53.7% of the sample. Over 44% had SRCCA metastasizing to regional lymph nodes, and tumors metastasizing to distant locations made up 61.3% of the sample. The mean and median tumor size at the time of diagnosis was 45.4 and 40 mm, respectively; 87% of the patients had tumors equal to or larger than 20 mm.

A total of 456 patients (86.5%) underwent surgery, ranging from partial colectomy to total colectomy. Surgery stratified by stage is shown in Table [2](#TAB2){ref-type="table"}. The most common surgery performed was subtotal colectomy (208 out of 456 patients, 45.6%), followed by partial colectomy (153 out of 456 patients, 33.6%), and total colectomy (81 out 456 patients, 17.8%).

###### Cohort characteristics

NOS: not otherwise specified; SD: standard deviation; n: number of patients

  ------------------------ --------------- -------- --------------- ------- --------------- -------
  Characteristic           Total           Female   Male                                    
  Patients, n              527             337      63.90%          190     36.10%          
  Age, years                                                                                
  Median                   56                       56                      56               
  Mean (SD)                57.22 (12.69)            57.05 (12.85)           57.52 (12.43)    
  Marital status, n                                                                         
  Married                  336             63.8%    202             59.9%   134             70.5%
  Unmarried                172             32.6%    120             35.6%   52              27.4%
  Unknown                  19              3.6%     15              4.5%    4               2.1%
  Race, n                                                                                   
  White                    439             83.3%    284             84.3%   155             81.6%
  Black and other          87              16.5%    52              15.4%   35              18.4%
  Unknown                  1               0.2%     1               0.3%                     
  Tumor grade, n                                                                            
  High grade               316             60%      204             60.5%   112             58.9%
  Low grade                41              7.8%     26              7.7%    15              7.9%
  Unknown                  170             32.3%    107             31.8%   63              33.2%
  Tumor size, mm                                                                            
  Median                   40                       40                      42               
  Mean (SD)                45.4 (27.77)             44.38 (29.22)           46.95 (25.45)    
  Primary tumor, n                                                                          
  T1                       13              2.5%     8               2.4%    5               2.6%
  T2                       6               1.1%     4               1.2%    2               1.1%
  T3                       140             26.6%    80              23.7%   60              31.6%
  T4                       283             83.9%    184             54.6%   99              52.1%
  Tx                       85              16.1%    61              18.1%   24              12.6%
  Regional lymph node, n                                                                    
  N0                       209             39.7%    130             38.6%   79              41.6%
  N1                       235             44.6%    146             43.3%   89              46.8%
  Nx                       83              15.7%    61              18.1%   22              11.6%
  Metastasis, n                                                                             
  M0                       199             37.8%    98              29.1%   101             53.2%
  M1                       323             61.3%    235             69.7%   88              46.3%
  Mx                       5               0.9%     4               0.2%    1               0.5%
  Surgery, n                                                                                
  No surgery               71              13.5%    49              14.5%   22              11.6%
  Partial colectomy        153             29%      95              28.2%   58              30.5%
  Subtotal colectomy       208             39.5%    113             33.5%   95              50%
  Total colectomy          81              15%      70              20.8%   11              5.8%
  Surgery NOS              14              2.7%     10              3%      4               2.1%
  ------------------------ --------------- -------- --------------- ------- --------------- -------

###### Surgery type stratified by stage

NOS: not otherwise specified; n: number of patients

  ---------------- ------------- ------------------- -------------------- -----------------
  Stage            No surgery    Partial colectomy   Subtotal colectomy   Total colectomy
  Stage I, n       2             3                   6                    0
  Stage II, n      3             38                  40                   7
  Stage III, n     0             16                  63                   9
  Stage IV, n      61            90                  99                   65
  Unspecified, n   5             6                   0                    0
  Total, n (%)     71 (13.47%)   153 (29.03%)        208 (39.48)          81 (15.37%)
  ---------------- ------------- ------------------- -------------------- -----------------

Table [3](#TAB3){ref-type="table"} demonstrates the results of multivariate Cox proportional hazards analyses for the mortality-associated risk factors in patients with SRCCA. Age \[hazard ratio (HR) = 1.02, 95% CI: (1.00, 1.03)\], T4 \[HR = 1.96, 95% CI: (1.29, 2.97)\], N1 \[HR = 1.90, 95% CI: (1.30, 2.77)\], and M1 \[HR = 2.62, 95% CI: (1.76, 3.91)\] were associated with an increased risk of mortality, while surgery, regardless to the extent, was a protective factor for survival: partial colectomy \[HR = 0.45, 95% CI: (0.25, 0.82)\], subtotal colectomy \[HR = 0.51, 95% CI: (0.28, 0.93)\] and total colectomy \[HR = 0.47, 95% CI: (0.24, 0.94)\].

###### Multivariate analysis results

AJCC: American Joint Committee on Cancer; CI: confidence interval

  ----------------------------------- -------------- -------------------- --------------------
                                      Hazard ratio   95% CI lower limit   95% CI upper limit
  Age, years                          1.02           1                    1.03
  Females vs. males                   1.33           0.96                 1.86
  AJCC T category: T4 vs. T1          1.96           1.29                 2.97
  AJCC N category: N1 vs. N0          1.9            1.3                  2.77
  AJCC M category: M1 vs. M0          2.62           1.76                 3.91
  Surgical treatment                                                      
  Partial colectomy vs. no surgery    0.45           0.25                 0.82
  Subtotal colectomy vs. no surgery   0.51           0.28                 0.93
  Total colectomy vs. no surgery      0.47           0.24                 0.94
  ----------------------------------- -------------- -------------------- --------------------

Three and five-year CSS probabilities for the 527 patients with SRCCA were 39% and 18.4%, respectively, and median survival was 26 months. A Kaplan-Meier curve for the cohort as a whole is shown in Figure [1](#FIG1){ref-type="fig"}. A Kaplan-Meier curve by sex is shown in Figure [2](#FIG2){ref-type="fig"}. Females showed three- and five-year CSS probabilities of 34.2% and 14.2%, respectively, while males exhibited three- and five-year CSS probabilities of 47.7% and 25.4%, respectively. Both race and marital status were not found to be associated with a statistically significant difference in survival.
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Survival probabilities by tumor grade are shown in Figure [3](#FIG3){ref-type="fig"}. Low-grade tumors (well-differentiated and moderately differentiated) are shown to have significantly better three- and five-year CSS probabilities compared to high-grade tumors (poorly differentiated and anaplastic); (70.1% and 44.8% vs. 36.8% and 15.4%, respectively). The median survival for low-grade tumors was 60 months, which was more than double the value for high-grade tumors (26 months, p\<0.001).
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Survival probabilities by tumor size are graphed as a Kaplan-Meier curve in Figure [4](#FIG4){ref-type="fig"}. Tumor size was found to significantly affect survival probabilities, with tumors less than 20 mm having better three- and five-year survival probabilities (68.5% and 50.5%, respectively) compared to tumors greater than or equal to 20 mm (38.7% and 14%, respectively) (p\<0.001).
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Survival probabilities by each component of the TNM classification are plotted as Kaplan-Meier curves in Figures [5](#FIG5){ref-type="fig"}-[7](#FIG7){ref-type="fig"}. As expected, T4, N1, and M1 had the worst survival probabilities. Table [4](#TAB4){ref-type="table"} lays out the detailed results. It is worth noting that the sample size for T1 and T2 accounted for the inability to estimate the median survival and survival probabilities. While three- and five-year CSS probabilities for T3 were 70% and 44.5%, respectively, for T4 there was a significant drop, 28.1% and 7.5%, respectively (p\<0.001). Regional lymph node involvement (N1) showed a median survival of 21 months (p\<0.001), while that for a patient with distant metastasis (M1) was 19 months (p\<0.001).
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![Cancer-specific survival for patients with SRCCA by AJCC TNM N category (n=444, p\<0.001)\
SRCCA: signet ring cell carcinoma of the appendix; AJCC: American Joint Committee on Cancer; cum: cumulative](cureus-0012-00000008549-i06){#FIG6}
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###### Three- and five-year survival probabilities

a: couldn't be calculated

\*Survival at 35 months

  --------------------- ---------------------------------------- ---------------------------------------
  Variable              Probability of three-year survival (%)   Probability of five-year survival (%)
  Overall               39.3                                     18.4
  Sex                                                            
  Female                34.2                                     14.2
  Male                  47.7                                     25.4
  Race                                                           
  White                 39                                       18
  Black and other       34.5                                     19
  Marital status                                                 
  Married               40.4                                     17.2
  Unmarried             34.5                                     19.1
  Grade                                                          
  Low grade             70.1                                     44.8
  High grade            36.8                                     15.4
  Tumor size                                                     
  \<20 mm               68.5                                     50.5
  ≥20 mm                38.7                                     14
  Primary tumor                                                  
  T1                    A                                        a
  T2                    a                                        a
  T3                    70                                       44.5
  T4                    28.1                                     7.5
  Regional lymph node                                            
  N0                    57                                       37.5
  N1                    30.2                                     7.1
  Metastasis                                                     
  M0                    64                                       40
  M1                    23                                       3.9
  Surgery extension                                              
  Partial colectomy     44.9\*                                   20.9
  Subtotal colectomy    48.5                                     26.5
  Total colectomy       24.4                                     3.4
  No surgery            12.5\*                                   6.2
  --------------------- ---------------------------------------- ---------------------------------------

Figure [8](#FIG8){ref-type="fig"} represents Kaplan Meier curves for different surgical treatments; all surgical interventions showed better CSS and median survival time compared to no surgery. Of all the surgical methods, subtotal colectomy had the highest median survival (35 months) and the best three- and five-year CSS (48.5% and 26.5%, respectively; p\<0.001), followed by partial colectomy with a median survival of 33 months and three- and five-year survival probabilities of 44.9% and 20.9%, respectively (p\<0.001). Total colectomy resulted in the worst three- and five-year survival outcomes at 24.4% and 3.4%, respectively (p\<0.001), and the worst median survival (19 months).
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Discussion
==========

Case reports and case series constitute most of the published literature on primary SRCCA. To the best of our knowledge, only three previously published studies have utilized the SEER database to address the appendiceal malignancies. McCusker et al. (2002) analyzed the demographic characteristics of patients with cancer of the appendix reported to the SEER database between 1973 and 1998; the study included 70 cases of SRCCA \[[@REF6]\]. The second study was done by Turaga et al. (2012) in which they compared the incidence and survival for the different histological subtypes of appendiceal cancers; the study covered the cohort of cases reported to the SEER between 1973 and 2007 and included 313 patients with SRCCA \[[@REF7]\]. The third study by McGory at el. (2005) was specific to the management and prognosis of adenocarcinoma of the appendix, and cases reported to SEER between 2004 and 2013 were included; According to the study, the adenocarcinoma included three subtypes: mucinous, non-mucinous, and signet cell; no specific numbers and statistics were given pertaining to each subtype \[[@REF8]\]. All of these studies emphasized the poor prognosis of SRCCA compared to other histologies. Due to the paucity of published research on this notorious cancer, we aimed to focus our study specifically on SRCCA to analyze the specific tumor and patient characteristics and to give survival statistics. Our cohort consisted of a total of 456 patients diagnosed between 2000 and 2015.

Turaga et al.\'s study (2012) showed a female-sex predominance (60%), which is consistent with our results (64%) \[[@REF7]\]. Although females have a worse CSS probability compared to males, such a difference was lost on the multivariate analysis. The majority of patients in our analysis were white, a finding consistent with all different histological subtypes of appendiceal malignancies \[[@REF6]-[@REF8]\]. Nevertheless, no statistically significant difference in survival was found based on race.

The effect of tumor size on survival for appendiceal malignancies has been examined. McGory at el. have stated that there is a statistically significant drop in five-year survival with increasing tumor size for noncarcinoid tumors in general (78% for tumors less than or equal to 1 cm vs. 43% for tumors more than 2 cm; p=0.04) and addressed the need for a more aggressive treatment approach (right hemicolectomy) rather than simple appendectomy \[[@REF8]\]. In our study, the five-year CSS for SRCCA showed a significant difference based on size, but such a difference was lost in the multivariate analysis, which may be due to the fact that the size of tumors for a lot of cases was not reported and was subsequently excluded from the analysis.

In a study addressing the importance of histological subtype in the staging of appendiceal tumors, Turaga et al. reported a median survival of 24 months for patients with SRCCA \[[@REF7]\]; our median survival was very close (26 months). Another study reported five-year overall survival rates of 18% and 7%, for all stages and for metastatic disease, respectively \[[@REF8]\]. In our analysis, the five-year CSS for all stages was 18.4, and for metastatic disease, it was 4%. Metastasis at presentation is more common for SRCCA than other histological subtypes. In the aforementioned three SEER studies, the percentage of metastatic disease at presentation was as follows; 60%, 76%, and 56% \[[@REF6]-[@REF8]\]. In our analysis, the percentage of metastatic disease fell between the percentages in previous studies, accounting for 61% of the cases.

SRCCA is managed similarly to other subtypes of appendiceal adenocarcinomas (mucinous type and intestinal or colonic type). In the absence of explicit surgical guidelines for the management of appendix cancer, management is largely guided by retrospective series \[[@REF1],[@REF9]\]. The question of whether a simple appendectomy is enough or if a hemicolectomy is needed remains controversial. A study that utilized the SEER database proposed a nomogram to predict five-year survival and guide the management of adenocarcinoma of the appendix; it suggested that depth of invasion should be used as a guide to the surgical intervention. The study showed that for tumors limited to the mucosa, there was no difference in the overall five-year survival between patients who underwent local tumor excisions, such as appendectomy, and those who chose extended surgery (hemicolectomy and more; p=0.752). On the other hand, for tumors that invaded the mucosa, patients who underwent extended surgery were found to have better overall survival compared to those who only underwent localized resection (p=0.011 for tumor invading the serosa, and p=0.956 for tumor that had invaded the serosa) \[[@REF1]\]. Other studies suggested a right hemicolectomy as the recommended surgical intervention for all SRCCA \[[@REF10]\]. Our analysis showed a five-year CSS of 26.5% for subtotal colectomy compared to 20.9% for partial colectomy (including appendectomy) with a p-value of \<0.001.

The role of adjuvant chemotherapy and radiotherapy in appendiceal adenocarcinoma in general, and in SRCCA in particular, remains uncertain. A retrospective study conducted at The University of Texas MD Anderson Cancer Center that involved 142 patients with poorly differentiated and signet ring cell adenocarcinomas of the appendix showed that systemic chemotherapy appears to be a viable treatment option for patients with metastatic disease (HR: 0.5; p=0.02) \[[@REF11]\].

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is the standard treatment for peritoneal dissemination (PD) from appendiceal cancer. PD of the SRCC is termed peritoneal mucinous carcinomatosis with signet ring cells (PMCA-S). In a retrospective study carried out at the Wake Forest Baptist Health to determine the significance of signet ring cells in mucinous adenocarcinoma of the peritoneum from the appendiceal origin, signet ring cells were identified in 29 of 55 cases. All of the 29 cases were high grade. A significant survival difference was seen for cases of high-grade mucinous adenocarcinoma with signet ring cells invading tissue with a median overall survival of 0.5 years versus 2.9 years for cases of high-grade mucinous adenocarcinoma without signet ring cells (p=0.04), and 2.4 years for high-grade mucinous adenocarcinoma with signet ring cells within mucin pools (p=0.03) \[[@REF12]\].

Given the poor prognosis of PD from SRCCA, the benefit of CRS/HIPEC in such cases has been questioned and results of the previous retrospective studies in that regard were not consistent. A retrospective study included 196 patients with PD from high-grade appendiceal malignancies, of whom 151 underwent successful CRS/HIPEC procedures, of which 82 % had a signet cell component. The study showed that CRS/HIPEC can achieve a five-year survival of 25% for a patient with PMCA-S, which may improve to 51% with negative lymph nodes. The study endorsed the treatment method \[[@REF13]\]. On the other hand, in another retrospective study conducted at the Washington Cancer Institute that included 494 patients with PMCA, of whom 80 had PMCA-S, the five-year overall survival for the latter group was 22% and the median survival time was 18.9 months. The independent predictors for a poor overall survival included incompleteness of cytoreduction, PMCA-S histomorphology, and distant metastasis \[[@REF14]\].

The management of SRCCA is mired in controversies, and many questions remain unanswered. Further research with a larger cohort of patients is needed to address these knowledge gaps regarding the management of SRCCA and to provide the most optimal treatment for the patients.

A major limitation of our study was its retrospective design. Data compiled in the database may have been incompletely, improperly, or inaccurately recorded from the patients' charts. Additionally, selection bias was inherent as only patients from certain registries were added. Finally, although stage reporting was done using two TNM AJCC staging editions (third and sixth) according to the year of diagnosis, authors do not believe that it has affected the results of the analysis as the two staging editions have the same TNM components for colonic cancers (appendicular cancers were not a separate diagnosis in these two editions), except for N3, which was considered in the third edition but no longer used in the sixth.

Conclusions
===========

In this study, we discussed the various features and survival rates of patients diagnosed with SRCCA. SRCCA is a rare tumor with a high prevalence among old-aged white females. This tumor is usually diagnosed in an advanced stage and has a dismal prognosis. Surgical intervention, regardless of the extent, showed better survival probabilities compared to no surgery.
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